| Literature DB >> 33668212 |
Jeanne Alard1, Benoit Cudennec2, Denise Boutillier1, Véronique Peucelle1, Amandine Descat3, Raphaël Decoin4, Sarah Kuylle5, Amin Jablaoui6, Moez Rhimi6, Isabelle Wolowczuk1, Bruno Pot1, Anne Tailleux4, Emmanuelle Maguin6, Sophie Holowacz7, Corinne Grangette1.
Abstract
Since alterations of the gut microbiota have been shown to play a major role in obesity, probiotics have attracted attention. Our aim was to identify probiotic candidates for the management of obesity using a combination of in vitro and in vivo approaches. We evaluated in vitro the ability of 23 strains to limit lipid accumulation in adipocytes and to enhance the secretion of satiety-promoting gut peptide in enteroendocrine cells. Following the in vitro screening, selected strains were further investigated in vivo, single, or as mixtures, using a murine model of diet-induced obesity. Strain Bifidobacterium longum PI10 administrated alone and the mixture of B. animalis subsp. lactis LA804 and Lactobacillus gasseri LA806 limited body weight gain and reduced obesity-associated metabolic dysfunction and inflammation. These protective effects were associated with changes in the hypothalamic gene expression of leptin and leptin receptor as well as with changes in the composition of gut microbiota and the profile of bile acids. This study provides crucial clues to identify new potential probiotics as effective therapeutic approaches in the management of obesity, while also providing some insights into their mechanisms of action.Entities:
Keywords: bile acids; enteroendocrine peptides; epithelial barrier; hypothalamus; inflammation; microbiota; obesity; probiotics
Mesh:
Substances:
Year: 2021 PMID: 33668212 PMCID: PMC7995962 DOI: 10.3390/nu13030713
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717